First-in-human Study Evaluating the Safety, Tolerability and Immunogenicity of i.n. Administration of a Personalized Vaccination With IVAC MUTANOME Vaccine w/o Initial Treatment With RBL001/RBL002 Vaccine in Patients With Advanced Melanoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs BNT 121 (Primary) ; RBL 001/RBL 002 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- Sponsors BioNTech; Ribological
- 31 Mar 2020 According to an BioNTech media release, updated data from this study were provided at the J.P. Morgan Health Care Conference in January 2020.
- 31 Mar 2020 Results published in the BioNTech Media Release.
- 14 Jan 2020 Status changed from active, no longer recruiting to completed.